Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET

Company Participants

Paul Little – Chief Financial Officer

David-Alexandre Gros – Chief Executive Officer

Steve Perrin – President and Chief Scientific Officer

Jeff Bornstein – Chief Medical Officer

Conference Call Participants

Pete Stavropoulos – Cantor Fitzgerald

Nat Charoensook – SVB

Matt Kaplan – Ladenburg Thalmann

Operator

Greetings, and welcome to Eledon Pharmaceuticals First Quarter Financial Results Conference Call. At this time all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded today, May 12, 2022.

I would now like to turn the conference call over to Paul Little, Chief Financial Officer of Eledon. Please go ahead.

Paul Little

Good afternoon everyone and thank you for joining Eledon’s first quarter 2022 operating and financial results conference call. I am joined on today’s call by David-Alexandre Gros, Chief Executive Officer; Steve Perrin, President and Chief Scientific Officer; and Jeff Bornstein, Chief Medical Officer. Earlier today, Eledon issued a press release announcing financial results for the first quarter ended March 31, 2022. You may access the release under the Investors tab on our company's website at eledon.com.

I would like to remind everyone that today – that statements made during this conference call relating to Eledon’s expected future performance, future business prospects or future events or plans may include forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All such forward-looking statements are intended to be subject to the safe harbor protection provided by the Reform Act. Actual outcomes and results could differ materially from those forecasts due to the impact of many factors beyond the control of Eledon. Eledon expressly disclaims any duty to provide updates to its forward-looking statements, whether as a result of new information, future events or otherwise. Participants are directed to the risk factors set forth in Eledon’s reports filed with the U.S. Securities and Exchange Commission.

Now I would like to pass the call to Eledon’s CEO, Dr. David-Alexandre Gros, DA.

David-Alexandre Gros

Thank you, Paul, and thank you all for joining the call today. We made important progress during the first quarter of 2022 and look forward to continuing this momentum through the remainder of the year. Our priority this year has been and remains executing on our four clinical trials in three therapeutic areas: neurodegeneration, focusing on ALS; transplantation, focusing on kidney and islet cell transplantation for type 1 diabetes; and autoimmunity focusing on IgA nephropathy, or IgAN.